Patent 7608686 was granted and assigned to ZymoGenetics on October, 2009 by the United States Patent and Trademark Office.
Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.”